Eribulin mesylate (Halaven) for breast cancer: positive effects predominate in certain patients, negative effects in others

Eribulin mesylate (Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed ...

Read more →

German proposal to report drug prices has Roche concerned

[:content [\1 \8 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \  \G \e \r \m \a \n \y \space \i \s \space \c \o \n \s \i \d \e \r \i \n \g \space \l \e \g \i \s \l \a \t \i \o \n \space \t \h \i \s \space \w \e \e \k \space \t \h \a \t \space \w \o \u \l \d \space \f \o \r \c \e \space \d \r \u \g \m \a \k \e \r \s \space \t \o \space \r \e \p \o \r \t \space \t \h \e \space \r \e \d \u \c \e \d \space \p \r \i \c \e \s \space \t \h \e \y \space \n \e \g \o \t \i \a \t \e " ..."]]
Read more →

Dasabuvir in hepatitis C: indication of added benefit in certain patients

The drug dasabuvir (trade name Exviera) has been available since January 2015 for the treatment of adults with chronic hepatitis ...

Read more →

IQWiG invites to its Autumn Symposium 2014

The introduction of the first disease management programmes was the starting point for providing a legal basis for evidence-based medicine ...

Read more →

Simoctocog alfa for haemophilia A: no suitable data

Simoctocog alfa (trade name Nuwiq) has been approved since July 2014 for people with type A haemophilia, an inherited disorder ...

Read more →

Perampanel for epilepsy: still no proof of added benefit

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive (“add-on”) therapy for adults and children ...

Read more →

Fingolimod in RRMS: indication of added benefit in certain patients

Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and ...

Read more →

Sofosbuvir shows an indication of additional benefit for certain patients

[:content [\2 \space \M \a \y \space \2 \0 \1 \4 \space \- \space \S \o \f \o \s \b \u \v \i \r \space \h \a \s \space \b \e \e \n \space \a \v \a \i \l \a \b \l \e \space \s \i \n \c \e \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \c \h \r \o \n \i \c \  \h \e \p \a \t \i \t \i \s \  \C \  \i \n \f \e \c \t \i \o \n \. \  \T \h \e \space \I \n \s \t \i \t \u \t \e \space \f \o \r \space \Q \u \a \l \i \t \y " ..."]]
Read more →

Empagliflozin in type 2 diabetes: added benefit not proven

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet ...

Read more →

Novartis is yet to commit to the possible withdrawal of Galvus (vildagliptin) following G-BA benefit assessment

[:content [\A \space \w \e \e \k \space \a \f \t \e \r \space \G \e \r \m \a \n \y \' \s \space \F \e \d \e \r \a \l \space \J \o \i \n \t \space \C \o \m \m \i \t \t \e \e \space \( \G \- \B \A \) \space \i \s \s \u \e \d \space \i \t \s \space \f \i \n \a \l \space \b \e \n \e \f \i \t \space \a \s \s \e \s \s \m \e \n \t \space \o \f \space \D \P \P \- \4 \space \i \n \h \i \b \i \t \o \r \s \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f " ..."]]
Read more →

Mirabegron for overactive bladder: additional benefits not covered

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. The Institute for Quality ...

Read more →

World's most expensive medicine: is it worth the price?

Is it worth $1 million to treat a potentially fatal genetic disease that causes painful swelling of the pancreas and ...

Read more →

Trastuzumab emtansine: indication of major added benefit in metastatic breast cancer with previous anthracycline therapy

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \space \T \h \e \space \a \n \t \i \b \o \d \y \- \d \r \u \g \space \c \o \n \j \u \g \a \t \e \space \t \r \a \s \t \u \z \u \m \a \b \space \e \m \t \a \n \s \i \n \e \space \( \t \r \a \d \e \space \n \a \m \e \: \space \K \a \d \c \y \l \a \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \s \i \n \c \e \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \f \o \r \space \t \h \e " ..."]]
Read more →

Albiglutide in type 2 diabetes: hint of minor added benefit

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet ...

Read more →

Rilpivirine combination product in HIV-1 patients with previous antiretroviral treatment: added benefit not proven

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \T \h \e \space \I \Q \W \i \G \  \r \e \a \s \s \e \s \s \e \d \space \t \h \e \space \a \n \t \i \v \i \r \a \l \space \d \r \u \g \space \c \o \m \b \i \n \a \t \i \o \n \space \r \i \l \p \i \v \i \r \i \n \e \/ \e \m \t \r \i \c \i \t \a \b \i \n \e \/ \t \e \n \o \f \o \v \i \r \. \space \I \n \space \e \a \r \l \y \space \2 \0 \1 \2 \, \space \t \h \e \space \c \o \m \b \i \n \a \t \i \o \n \space \w \a \s \space \a \p \p \r \o \v \e \d \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t " ..."]]
Read more →